Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Src family kinases (SFK) are involved in regulating a multitude of biological processes, including cell adhesion, migration, proliferation, and survival, depending on the cellular context. Therefore, although SFKs are currently being investigated as potential targets for treatment strategies in various cancers, the biological responses to inhibition of SFK signaling in any given tumor type are not predictable. Dasatinib (BMS-354825) is a dual Src/Abl kinase inhibitor with potent antiproliferative activity against hematologic malignancies harboring activated BCR-ABL. In this study, we show that dasatinib blocks migration and invasion of human melanoma cells without affecting proliferation and survival. Moreover, dasatinib completely inhibits SFK kinase activity at low nanomolar concentrations in all eight human melanoma cell lines investigated. In addition, two known downstream targets of SFKs, focal adhesion kinase and Crk-associated substrate (p130CAS), are inhibited with similar concentrations and kinetics. Consistent with inhibition of these signaling pathways and invasion, dasatinib down-regulates expression of matrix metalloproteinase-9. We also provide evidence that dasatinib directly inhibits kinase activity of the EphA2 receptor tyrosine kinase, which is overexpressed and/or overactive in many solid tumors, including melanoma. Thus, SFKs and downstream signaling are implicated as having key roles in migration and invasion of melanoma cells. (Mol Cancer Res 2008;6(11):1766–74)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 1×
“The antitumor potency of dasatinib has been shown in early- and late-phase clinical trials for chronic myelogeneous leukemia (22, 23).”
BackgroundDNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“The prototype SFK is c-Src, which is a protein tyrosine kinase from which the oncogenic viral Src (v-Src) is derived (8).”
BackgroundYeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · cited 1×
“Introduction Increased protein levels and kinase activities of Src family kinases (SFK) have been observed in a wide diversity of human cancers, including melanoma, breast, ovarian, and lung cancer (1-7).”
BackgroundSrc family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
Niu, G., Bowman, T., Huang, M., Shivers, S., Reintgen, D., Daud, A., Chang, A., Kraker, A., Jove, R., & Yu, H. (2002) · Oncogene · doi:10.1038/sj.onc.1205859 · Cited by 432
Self-citationActivation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393 · cited 1×
“Multiple factors involved in invasion and metastasis of melanoma cells have been described (41, 42);”
BackgroundJones, R. J., Avizienyte, E., Wyke, A. W., Owens, D. W., Brunton, V. G., & Frame, M. C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600594 · Cited by 80 · cited 2×
“Discussion SFKs participate in the regulation of many different biological processes, including cell adhesion, motility, invasion, differentiation, proliferation, and survival (9-17).”
Background
Cited by
Src signaling in cancer invasion
Guarino, M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22011 · Cited by 426
The Role of Src in Solid Tumors
Wheeler, D. L., Iida, M., & Dunn, E. F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0009 · Cited by 346
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors
Araujo, J., & Logothetis, C. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.015 · Cited by 244
Morton, J. P., Karim, S. A., Graham, K., Timpson, P., Jamieson, N., Athineos, D., Doyle, B., McKay, C., Heung, M., Oien, K. A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.034 · Cited by 148
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Martellucci, S., Clementi, L., Sabetta, S., Mattei, V., Botta, L., & Angelucci, A. (2020) · Cancers · doi:10.3390/cancers12061448 · Cited by 139
“Other authors confirmed in melanoma cells the prominent role of Src in migration and invasion respect to proliferation, showing an effective role in stimulating MMPs release and phosphorylation of Fak and p130CAS [109].”
Metadata
- Authors
- Buettner, R., Mesa, T., Vultur, A., Lee, F., & Jove, R.
- Venue
- Molecular Cancer Research
- Published
- 2008-11-01
- Volume
- 6
- Issue
- 11
- Pages
- 1766-1774
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- OpenAlex
- W2132541027
- Cited by
- 123
- References
- 7
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-08-0169
- The paper
- Buettner, R., Mesa, T., Vultur, A., Lee, F., & Jove, R. (2008). Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-08-0169
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.